Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Polpharma SA
In a blow to several generics firms – albeit one telegraphed by a decision handed down nine months ago – the European Commission has ordered the removal of marketing authorizations for generic versions of Biogen’s MS brand, Tecfidera.
Formycon has announced the approval of its biosimilar ranibizumab by Health Canada, with commercial launch by Teva expected to begin in Q1 next year.
Fourteen new products could be approved in the EU soon, after the European Medicines Agency gave them the thumbs up.
At an eventful European Medicines Agency committee meeting in July, three biosimilars from Biocon, Sandoz and Fresenius Kabi have become the first for each respective molecule – aflibercept, natalizumab and tocilizumab – to gain the endorsement of the CHMP.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Polpharma Biologics
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.